|
Stephen Carter. M.D., joined the Alfacell Board of Directors in May 1997. Dr. Carter has over 30 years of experience in oncology research and development in academia and industry. Dr. Carter most recently served as Senior Vice President, Clinical and Regulatory Affairs for SUGEN, Inc., a San Francisco-based biotechnology and pharmaceutical company, now a subsidiary of Pfizer. Prior to SUGEN, he was Senior Vice President, Research & Development, for Boehringer Ingelheim Pharmaceuticals, Inc. from 1995 to 1997. From 1982 to 1995, Dr. Carter served in several executive roles in R&D at Bristol-Myers Squibb Company, including five years as Senior Vice President, Worldwide Clinical Research & Development, Pharmaceutical Research Institute, and played a leading role in gaining regulatory approval for widely-used anticancer and AIDS therapies. From 1976 to 1982, he established and directed the Northern California Cancer Program. Prior to this, he held a number of positions at the National Cancer Institute from 1967 to 1976, including the position of Deputy Director at the National Institutes of Health. He has also been a faculty member of the medical schools of Stanford University, the University of California at San Francisco, and New York University. Dr. Carter has published extensively on the development of anticancer drugs, was the co-founding editor of journals devoted to cancer therapeutics or immunology, and has served on the editorial boards of a number of additional journals dedicated to cancer treatment. He is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), and the Society for Surgical Oncology. Dr. Carter earned his B.A. from Columbia University and his M.D. from New York Medical College.
| 